Skip to main content

Fiscal Wizard · Single-issue tearsheet

LEXX / Jun 22, 2026 Run #7683

LEXX

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Composite verdict

F 10.6 / 100
Bearish setup · Trend Following 12 drivers · 6 gates blocking
  • Rate of Change
  • Vortex Signal
  • Coppock Curve
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 427th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 4Mean-reversion Neutral 48

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

21.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Return on Capital Employed 0
Gross Margin 75
Return on Assets 0
P/B 75
Greenblatt ROC 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Vortex Signal, Coppock Curve); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 9
Vortex Signal 13
MACD Signal Cross 14

Risk Gates

6 blocking 4 caution

6 guards active, 19 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LEXX.